CXCR2-transduced T cells

CXCR2-transduced T cells are **T lymphocytes genetically engineered to express the chemokine receptor CXCR2**. This genetic modification is typically performed by **transducing T cells (often tumor-specific or tumor-infiltrating lymphocytes, TILs) with a retroviral or lentiviral vector encoding the CXCR2 gene**[1][2][3][4]. **CXCR2 is a G protein–coupled receptor for chemokines such as CXCL1 and CXCL8** (also known as IL-8), which are commonly expressed in the tumor microenvironment of various cancers, including melanoma[1][2][4]. **Mechanism of Action:** The engineered expression of CXCR2 enhances the T cells' chemotactic response, thereby improving their migration (homing) into tumors expressing relevant chemokine ligands[1][2]. This approach is designed to overcome one of the main limitations of adoptive cell therapy (ACT)—the inefficient trafficking of transferred T cells into tumor sites. Experimental and preclinical models have shown that CXCR2-transduced T cells accumulate more efficiently within tumors, resulting in improved antitumor immune responses and increased survival in animal models[1][2][4]. **Clinical Status:** CXCR2-transduced T cells have entered early-phase (Phase 1/2) clinical trials for melanoma and potentially other cancers, with the primary aim of improving efficacy of ACT by enhancing tumor infiltration of T cells[3].

Other names

CXCR2-engineered T cellsCXCR-2-engineered T cellsCXCR 2-engineered T cellsCXCR2-expressing T cellsCXCR-2-expressing T cellsCXCR 2-expressing T cellsCXCR2 gene-modified T cellsCXCR-2 gene-modified T cellsCXCR 2 gene-modified T cells